<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645384</url>
  </required_header>
  <id_info>
    <org_study_id>01621/09-10</org_study_id>
    <nct_id>NCT01645384</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions</brief_title>
  <official_title>An Open-label, Randomized, Single Oral Dose, Two Way Crossover Bioequivalence Study of Atorvastatin Ca 40 mg Tablets of Dr.Reddy's With Lipitor® 40 mg Tablets of Pfizer in 74 Healthy, Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor clinical status, adverse events and laboratory
      investigations and assess relative safety and tolerance of Atorvastatin formulations under
      fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, single oral dose, two way crossover bioequivalence study to
      compare Atorvastatin Calcium 40 mg Tablets of Dr.Reddy's with Lipitor® 40 mg Tablets of
      Pfizer in 74 healthy, adult, human study participants under fasting conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose at 0.00, 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 hours and 48.00 hours post dose.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Atorvastatin Calcium Tablets, 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipitor® 40 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium Tablets, 40 mg</intervention_name>
    <description>Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Atorvastatin Calcium Tablets, 40 mg</arm_group_label>
    <arm_group_label>Lipitor® 40 mg Tablets</arm_group_label>
    <other_name>Lipitor® 40 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  He/She should provide written informed consent.

          -  He/She must be a healthy adult within 18-45 years of age (inclusive).

          -  He/She should have a Body mass index of ≥ 18.5 kg/m2 and ≤ 25 kg/m2, with body weight
             not less than 50 kg.

          -  He/She should have a systolic blood pressure with upper limit of less than 140 mmHg
             and lower limit of more than or equal to 90 mm Hg. Similarly diastolic blood pressure
             with upper limit less than 90 mm Hg and lower limit more than or equal to 60 mmHg.

          -  He/She must be of normal health as determined by medical history and physical
             examination performed within 21 days prior to the dosing of period 1.

          -  He/She should have a normal ECG, chest X-ray and vital signs.

          -  Availability of a study volunteer for the entire study period and willingness to
             adhere to protocol requirements as evidenced by written informed consent.

          -  If study volunteer is a female and is of child bearing potential practicing an
             acceptable method of birth control for the duration of the study as judged by the
             investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device(IUD),
             or abstinence. or is postmenopausal for at least 1 year. or is surgically sterile
             (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed
             on the study volunteers)

        Exclusion Criteria:

          -  He/She is incapable of understanding the informed consent.

          -  He/She has a history of hypersensitivity or idiosyncratic reaction to study drug or
             any other related drug.

          -  He/She has any evidence of impairment of renal, hepatic, cardiac, lung or
             gastrointestinal function. Study volunteers with a history of tuberculosis,
             epilepsy,asthma (during past 5 years), diabetes, psychosis or glaucoma will not be
             eligible for the study.

          -  He/She smokes regularly more than ten cigarettes daily and has difficulty in
             abstaining from smoking for the duration of each study period.

          -  He/She has taken over the counter or prescribed medications, including any enzyme
             modifying drugs or any systemic medication within the past 30 days prior to dosing in
             first period.

          -  He/She has a history of any psychiatric illness, which may impair the ability to
             provide written, informed consent.

          -  He/She has a history of alcohol or substance abuse within the last 5 years.

          -  He/She has clinically significant abnormal values of laboratory parameters.

          -  He/She has participated in any other clinical investigation using experimental drug or
             had bled more than 350 mL in the past 3 months.

          -  He/She is unable to or likely to be non-compliant with protocol requirements or
             restrictions.

          -  He/She, in whom study drug is contraindicated for medical reasons

          -  He/She is intolerant to venipuncture.

          -  Female volunteer who has used implanted or injected hormonal contraceptives anytime
             during the 6 months prior to study or used hormonal contraceptives within 14 days
             before dosing.

          -  Female volunteer demonstrates a positive pregnancy screen. Each female study volunteer
             will be screened for pregnancy at screening, check-in each study period. Study
             volunteer with a positive or inconclusive result will be withdrawn from the study.

          -  Female volunteer is currently breast feeding. Female study volunteer who is pregnant,
             breast-feeding or who is likely to become pregnant during the study will not be
             allowed to participate. Female study volunteer of child bearing potential must either
             abstain from sexual intercourse or use a reliable barrier method (e.g. condom, IUD) of
             contraception during the course of the study (first dosing until last blood
             collection) or she will not be allowed to participate.

          -  He/She has a positive urine screen for drugs of abuse at the time of admission
             check-in for each period will be excluded from the study.

          -  He/She, who meets the inclusion and exclusion criteria, will be verified by medical
             investigator as per source documents duly authenticated by them reflecting clinical
             judgment as and when required
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sudarshan Vishwanath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vimta Labs Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Atorvastatin calcium</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

